Myotubular/centronuclear myopathy and central core disease

Neurology India

Volumn 56, Issue 3, 2008, Pages 325-332

  Fujimura Kiyono, Chieko ^a   Racz, Gabor ^a   Nishino, Ichizo ^a  

^a NATIONAL INSTITUTE OF NEUROSCIENCE   (Japan)

Author keywords

Central core disease; Centronuclear myopathy; Congenital myopathy; Congenital neuromuscular disease with uniform Type 1 fibers; Myotubular myopathy

Indexed keywords

BETA ADRENERGIC RECEPTOR STIMULATING AGENT;

AUTOSOMAL DOMINANT DISORDER; CENTRAL CORE DISEASE; CENTRONUCLEAR MYOPATHY; CONGENITAL DISORDER; GENE MUTATION; HEREDITARY MOTOR SENSORY NEUROPATHY; HUMAN; MUSCLE BIOPSY; NEUROMUSCULAR DISEASE; PHYSIOTHERAPY; REVIEW;

HUMANS; MUSCLE FIBERS, SKELETAL; MYOPATHIES, STRUCTURAL, CONGENITAL; MYOPATHY, CENTRAL CORE;

EID: 56049125724     PISSN: 00283886     EISSN: 19984022     Source Type: Journal    
DOI: 10.4103/0028-3886.43451     Document Type: Review

References (67)

1. Wallgren-Pettersson C: Congenital nemaline myopathy: A longitudinal study. In Commentationes Physico Mathematicae University of Helsinki; 1990.
2. Wallgren-Pettersson C, Clarke A, Samson F, Fardeau M, Dubowitz V, Moser H, et al. The myotubular myopathies: Differential diagnosis of the X linked recessive, autosomal dominant, and autosomal recessive forms and present state of DNA studies. J Med Genet 1995;32:673-9.
3. Pierson CR, Tomczak K, Agrawal P, Moghadaszadeh B, Beggs AH. X-linked myotubular and centronuclear myopathies. J Neuropathol Exp Neurol 2005;64:555-64.
4. Spiro AJ, Shy GM, Gonatas NK. Myotubular myopathy: Persistence of fetal muscle in an adolescent boy. Arch Neurol 1966;14:1-14.
5. Echaniz-Laguna A, Nicot AS, Carré S, Franques J, Tranchant C, Dondaine N, et al. Subtle central and peripheral nervous system abnormalities in a family with centronuclear myopathy and a novel dynamin 2 gene mutation. Neuromuscul Disord 2007;17:955-9.
6. Laporte J, Biancalana V, Tanner SM, Kress W, Schneider V, Wallgren-Pettersson C, et al. MTM1 mutations in X-linked myotubular myopathy. Hum Mutat 2000;15:393-409.
7. Taylor GS, Maehama T, Dixon JE. Inaugural article: myotubularin, a protein tyrosine phosphatase mutated in myotubular myopathy, dephosphorylates the lipid second messenger, phosphatidylinositol 3-phosphate. Proc Natl Acad Sci USA 2000;97:8910-5.
8. Blondeau F, Laporte J, Bodin S, Superti-Furga G, Payrastre B, Mandel JL. Myotubularin, a phosphatase deficient in myotubular myopathy, acts on phosphatidylinositol 3-kinase and phosphatidylinositol 3-phosphate pathway. Hum Mol Genet 2000;9:2223-9.
9. Buj-Bello A, Laugel V, Messaddeq N, Zahreddine H, Laporte J, Pellissier JF, et al. The lipid phosphatase myotubularin is essential for skeletal muscle maintenance but not for myogenesis in mice. Proc Natl Acad Sci USA 2002;99:15060-5.
10. McEntagart M, Parsons G, Buj-Bello A, Biancalana V, Fenton I, Little M, et al. Genotype-phenotype correlations in X-linked myotubular myopathy. Neuromuscul Disord 2002;12:939-46.
11. Biancalana V, Caron O, Gallati S, Baas F, Kress W, Novelli G, et al. Characterization of mutations in 77 patients with X-linked myotubular myopathy, including a family with a very mild phenotype. Hum Genet 2003;112:135-42.
12. Tanner SM, Orstavik KH, Kristiansen M, Lev D, Lerman-Sagie T, Sadeh M, et al. Skewed X-inactivation in a manifesting carrier of X-linked myotubular myopathy and in her non-manifesting carrier mother. Hum Genet 1999;104:249-53.
13. Hammans SR, Robinson DO, Moutou C, Kennedy CR, Dennis NR, Hughes PJ, et al. A clinical and genetic study of a manifesting heterozygote with X-linked myotubular myopathy. Neuromuscul Disord 2000;10:133-7.
14. Herman GE, Finegold M, Zhao W, de Gouyon B, Metzenberg A. Medical complications in long-term survivors with X-linked myotubular myopathy. J Pediatr 1999;134:206-14.
15. Helliwell TR, Ellis IH, Appleton RE. Myotubular myopathy: Morphological, immunohistochemical and clinical variation. Neuromuscul Disord 1998;8:152-61.
16. Pierson CR, Agrawal PB, Blasko J, Beggs AH. Myofiber size correlates with MTM1 mutation type and outcome in X-linked myotubular myopathy. Neuromuscul Disord 2007;17:562-8.
17. Nadeau A, D'Anjou G, Debray G, Robitaille Y, Simard LR, Vanasse M. A newborn with spinal muscular atrophy type 0 presenting with a clinicopathological picture suggestive of myotubular myopathy. J Child Neurol 2007;22:1301-4.
18. Bitoun M, Maugenre S, Jeannet PY, Lacène E, Ferrer X, Laforêt P, et al. Mutations in dynamin 2 cause dominant centronuclear myopathy. Nat Genet 2005;37:1207-9.
19. Jones SM, Howell KE, Henley JR, Cao H, McNiven MA. Role of dynamin in the formation of transport vesicles from the trans-Golgi network. Science 1998;279:573-7.
20. Praefcke GJ, McMahon HT. The dynamin superfamily: Universal membrane tubulation and fission molecules? Nat Rev Mol Cell Biol 2004;5:133-47.
21. Orth JD, McNiven MA. Dynamin at the actin-membrane interface. Curr Opin Cell Biol 2003;15:31-9.
22. Thompson HM, Cao H, Chen J, Euteneuer U, McNiven MA. Dynamin 2 binds gamma-tubulin and participates in centrosome cohesion. Nat Cell Biol 2004;6:335-42.
23. Bitoun M, Bevilacqua JA, Prudhon B, Maugenre S, Taratuto AL, Monges S, et al. Dynamin 2 mutations cause sporadic centronuclear myopathy with neonatal onset. Ann Neurol 2007;62:666-70.
24. Züchner S, Noureddine M, Kennerson M, Verhoeven K, Claeys K, De Jonghe P, et al. Mutations in the pleckstrin homology domain of dynamin 2 cause dominant intermediate Charcot-Marie-Tooth disease. Nat Genet 2005;37:289-94.
25. Fabrizi GM, Ferrarini M, Cavallaro T, Cabrini I, Cerini R, Bertolasi L, et al. Two novel mutations in dynamin-2 cause axonal Charcot-Marie-Tooth disease. Neurology 2007;69:291-5.
26. Tosch V, Rohde HM, Tronchère H, Zanoteli E, Monroy N, Kretz C, et al. A novel PtdIns3P and PtdIns(3,5)P2 phosphatase with an inactivating variant in centronuclear myopathy. Mol Genet 2006;15:3098-106.
27. Nicot AS, Toussaint A, Tosch V, Kretz C, Wallgren-Pettersson C, Iwarsson E, et al. Mutations in amphiphysin 2 (BIN1) disrupt interaction with dynamin 2 and cause autosomal recessive centronuclear myopathy. Nat Genet 2007;39:1134-9.
28. Jungbluth H, Zhou H, Sewry CA, Robb S, Treves S, Bitoun M, et al. Centronuclear myopathy due to a de novo dominant mutation in the skeletal muscle ryanodine receptor (RYR1) gene. Neuromuscul Disord 2007;17:338-45.
29. Jeannet PY, Bassez G, Eymard B, Laforêt P, Urtizberea JA, Rouche A, et al. Clinical and histologic findings in autosomal centronuclear myopathy. Neurology 2004;62:1484-90.
30. Fischer D, Herasse M, Bitoun M, Barragán-Campos HM, Chiras J, Laforêt P, et al. Characterization of the muscle involvement in dynamin 2-related centronuclear myopathy. Brain 2006;129:1463-9.
31. Magee KR, Shy GM. A new congenital non-progressive myopathy. Brain 1956;79:610-21.
32. Greenfield JG, Cornman T, Shy GM. The prognostic value of the muscle biopsy in the floppy infant. Brain 1958;81:461-84.
33. Dubowitz V, Pearse AG. Oxidative enzymes and phosphorylase in central-core disease of muscle. Lancet 1960;2:23-4.
34. Seitelberger F, Wanko T, Gavin MA. The muscle fiber in central-core disease. Histochemical and electronmicroscopic observations. Acta Neuropath. (Berlin) 1962;1:223-37.
35. Phillips MS, Fujii J, Khanna VK, DeLeon S, Yokobata K, de Jong PJ, et al. The structural organization of the human skeletal muscle ryanodine receptor (RYR1) gene. Genomics 1996;34:24-41.
36. Wagenknecht T, Grassucci R, Frank J, Saito A, Inui M, Fleischer S. Three-dimensional architecture of the calcium channel/foot structure of sarcoplasmic reticulum. Nature 1989;338:167-70.
37. Robinson R, Carpenter D, Shaw MA, Halsall J, Hopkins P. Mutations in RYR1 in malignant hyperthermia and central core disease. Hum Mutat 2006;27:977-89.
38. Jungbluth H, Zhou H, Sewry CA, Robb S, Treves S, Bitoun M, et al. Centronuclear myopathy due to a de novo dominant mutation in the skeletal muscle ryanodine receptor (RYR1) gene. Neuromuscul Disord 2007;17:338-345.
39. Denborough MA, Dennett X, Anderson RM. Central-core disease and malignant hyperpyrexia. Br Med J 1973;1:272-3.
40. Wu S, Ibarra MC, Malicdan MC, Murayama K, Ichihara Y, Kikuchi H, et al. Central core disease is due to RYR1 mutations in more than 90% of patients. Brain 2006;129:1470-80.
41. Romero NB, Monnier N, Viollet L, Cortey A, Chevallay M, Leroy JP, et al. Dominant and recessive central core disease associated with RYR1 mutations and fetal akinesia. Brain 2003;126:2341-9.
42. Zhou H, Brockington M, Jungbluth H, Monk D, Stanier P, Sewry CA, et al. Epigenetic allele silencing unveils recessive RYR1 mutations in core myopathies. Am J Hum Genet 2006;79:859-68.
43. Monnier N, Marty I, Faure J, Castiqlioni C, Desnuelle C, Sacconi S, et al. Null mutations causing depletion of the type 1 ryanodine receptor (RYR1) are commonly associated with recessive structural congenital myopathies with cores. Hum Mutat 2008;29:670-8.
44. Lynch PJ, Tong J, Lehane M, Mallet A, Giblin L, Heffron JJ, et al. A mutation in the transmembrane/luminal domain of the ryanodine receptor is associated with abnormal Ca2+ release channel function and severe central core disease. Proc Natl Acad Sci USA 1999;96:4164-9.
45. Bernardi P, Rasola A. Calcium and cell death: The mitochondrial connection. Subcell Biochem 2007;45:481-506.
46. Rossi AE, Dirksen RT. Sarcoplasmic reticulum: The dynamic calcium governor of muscle. Muscle Nerve 2006;33:715-31.
47. Fananapazir L, Dalakas MC, Cyran F, Cohn G, Epstein ND. Missense mutations in the beta-myosin heavy-chain gene cause central core disease in hypertrophic cardiomyopathy. Proc Natl Acad Sci USA 1993;90:3993-7.
48. Quinlivan RM, Muller CR, Davis M, Laing NG, Evans GA, Dwyer J, et al. Central core disease: Clinical, pathological, and genetic features. Arch Dis Child 2003;88:1051-5.
49. Dubowitz V, Platts M. Central core disease of muscle with focal wasting. J Neurol Neurosurg Psychiatry 1965;28:432-7.
50. Gamble JG, Rinsky LA, Lee JH. Orthopaedic aspects of central core disease. J Bone Joint Surg Am 1988;70:1061-6.
51. Ramsey PL, Hensinger RN. Congenital dislocation of the hip associated with central core disease. J Bone Joint Surg Am 1975;57:648-51.
52. Eng GD, Epstein BS, Engel WK, McKay DW, McKay R. Malignant hyperthermia and central core disease in a child with congenital dislocating hips. Arch Neurol 1978;35:189-97.
53. Sestero AM, Perra JH. A case report of severe kyphoscoliosis and autofusion of the posterior elements in two siblings with central core disease. Spine 2005;30:E50-5.
54. Isaacs H, Heffron JJ, Badenhorst M. Central core disease: A correlated genetic, histochemical, ultramicroscopic, and biochemical study. J Neurol Neurosurg Psychiatry 1975;38:1177-86.
55. Jungbluth H, Davis MR, Müller C, Counsell S, Allsop J, Chattopadhyay A, et al. Magnetic resonance imaging of muscle in congenital myopathies associated with RYR1 mutations. Neuromuscul Disord 2004;14:785-90.
56. Arai Y, Sumida S, Osawa M, Hirasawa K, Okada N, Kawai M, et al. Skeletal muscle CT scan and ultrasound imaging in two siblings with central core disease. No To Hattatsu 1990;22:55-60.
57. Robinson RL, Brooks C, Brown SL, Ellis FR, Halsall PJ, Quinnell RJ, et al. RYR1 mutations causing central core disease are associated with more severe malignant hyperthermia in vitro contracture test phenotypes. Hum Mutat 2002;20:88-97.
58. Sewry CA, Müller C, Davis M, Dwyer JS, Dove J, Evans G, et al. The spectrum of pathology in central core disease. Neuromuscul Disord 2002;12:930-8.
59. Scacheri PC, Hoffman EP, Fratkin JD, Semino-Mora C, Senchak A, Davis MR, et al. A novel ryanodine receptor gene mutation causing both cores and rods in congenital myopathy. Neurology 2000;55:1689-96.
60. Gonatas NK, Perez MC, Shy GM, Evangelista I. Central "core" disease of skeletal muscle ultrastructural and cytochemical observations in two cases. Am J Pathol 1965;47:503-24.
61. Hayashi K, Miller RG, Brownell AK. Central core disease: Ultrastructure of the sarcoplasmic reticulum and T-tubules. Muscle Nerve 1989;12:95-102.
62. Oh SJ, Danon MJ. Nonprogressive congenital neuromuscular disease with uniform type 1 fiber. Arch Neurol 1983;40:147-50.
63. Sato I, Wu S, Ibarra MC, Hayashi YK, Fujita H, Tojo M, et al. Congenital neuromuscular disease with uniform type 1 fiber and RYR1 mutation. Neurology 2008;70:114-22.
64. Jong YJ, Huang SC, Liu GC, Chiang CH. Mental retardation in congenital nonprogressive myopathy with uniform type 1 fibers. Brain 1991;13:444-6.
65. Caruso JF, Signorile JF, Perry AC, Leblanc B, Williams R, Clark M, et al. The effects of albuterol and isokinetic exercise on the quadriceps muscle group. Med Sci Sports Exerc 1995;27:1471-6.
66. Messina S, Hartley L, Main M, Kinali M, Jungbluth H, Muntoni F, et al. Pilot trial of salbutamol in central core and multi-minicore diseases. Neuropediatrics 2004;35:262-6.
67. Kissel JT, Mendell JR, Griggs RC, McDermott M, Tawil R; The FSH-DY group. Open-label clinical trial of albuterol in facioscapulohumeral muscular dystrophy. Neurology 1998;50:1402-6.